Glaxo’s pandemic influenza vaccine is characterised by regulatory authorities as a susbtance that needs to be stockpiled in the EU’s and USA’s biodefense stockpiles.
EU666 Biodefense stockpile
US666 Biodefense stockpile ”
This classificiation by regulatory authorities underscores fears that the pandemic flu vaccines, which contain toxic adjuvants, are indeed actually bioweapons, designed to cause death and injury. Furthermore, the Glaxo vaccine is categorised as having “controlled or government distribution in the EU and USA” only. Below is the entry for the Glaxo pandemic influenza vaccine on a biopharma database. Scroll down to see the Regulatory/Status Index.
“Prepandrix; Pandemrix – influenza virus H5N1, inactivated, vaccine, with AS03 adjuvant; bird flu vaccine; avian influenza vaccine; pandemic influenza vaccine”
Centers for Disease Control and Prevention (CDC) — R&D ; Tech. ; USA mark.
GlaxoSmithKline Biologicals S.A. (GSK) — Manuf. ; R&D ; Tech. ; Europe mark.
GlaxoSmithKline plc (GSK) — Parent
Monograph size = 15988 characters (not including indexing, nomenclature, links, etc. on this page)
Partial monograph text:
393 Influenza Vaccine, H5N1/GSK
Pandemic Influenza vaccine, surface antigen, inactivated; influenza vaccine, pandemic – Prepandrix; Pandemrix; influenza virus H5N1 vaccine; bird flu vaccine; influenza virus H5N1, inactivated, vaccine; avian influenza vaccine; influenza H5N1 virus (A/Indonesia) vaccine
Status: vaccine approved in EU in May 2008; being added to U.S. and other countries’ stockpiles
GlaxoSmithKline Biologicals S.A. – Manuf.: R&D; Tech.; Europe mark.
GlaxoSmithKline plc – Parent
Centers for Disease Control & Prevention (CDC) – R&D; Tech.; U.S. mark..
Description: Prepandrix “prepandemic vaccine” is a conventional egg-cultured influenza virus H5N1 (A/VietNam/1194/2005 NIBRG-14) clade 2 inactivated split-antigen vaccine. The H5N1 clade 2 bulk material is being manufactured from a laboratory version seed virus of the wild-type virus provided by the U.S. Centers for Disease Control and Prevention (CDC). The reference virus, A/Vietnam/1194/2004 (H5N1) NIBRG-14, was developed using reverse genetics, with reassortment strain combining the H5 and N1 segments to with an influenza virus PR8 strain backbone. In addition the H5 was engineered to eliminate the polybasic stretch of amino-acids at the HA cleava … truncated (just the beginning)
Infleunza Vaccine, H5N1/GSK [BIO]
Pandemic Influenza vaccine, surface antigen, inactivated [EU]
Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) A/VietNam/1194/2004 NIBRG-14 [EU]
Pandemic influenza vaccine (H5N1) (split, inactivated, adjuvanted) [EU]
avian influenza vaccine [SY]
bird flu vaccines [SY]
influenza H5N1 virus (A/Indonesia)vaccine [SY]
influenza vaccine, pandemic [SY]
influenza virus H5N1, inactivated, vaccine with AS03 adjuvant [SY]
Product Class Index:
bovine materials used
chicken source materials
SB001 BIOPHARMA prod. (mainstream)
EU200 Currently Approved in EU
EU666 Biodefense stockpile
UM100 Controlled/Gov’t Distribution in US
US666 Biodefense stockpile
EM160 Controlled/Gov’t Distribution in EU
chicken embryos (eggs)
influenza virus, H5N1
polysorbate 80 (Tween 80
potassium dihydrogen phosphate